Added to YB: 2026-05-12
Pitch date: 2026-05-10
LRMR [bullish]
Larimar Therapeutics, Inc.
+2.25%
current return
Author Info
No bio for this author
Company Info
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform.
Market Cap
$412.4M
Pitch Price
$4.00
Price Target
7.12 (+79%)
Dividend
N/A
EV/EBITDA
-1.63
P/E
-1.75
EV/Sales
N/A
Sector
Biotechnology
Category
growth
All FXN, No Fiction: Investigating Larimar Therapeutics
LRMR: Lead asset nomlabofusp is 1st-ever mitochondrial-targeted FXN replacement for Friedreich's Ataxia. BLA filing June 2026 targeting accelerated approval H1 2027. 100% pts on 50mg hit carrier-level skin FXN at 6mo; 1yr mFARS +2.25 vs -1.00 FACOMS natural history (~3.25pt swing, beats Skyclarys' 2.4pt). FDA granted Breakthrough Therapy, START, RMAT, orphan, Fast Track. EMA PRIME. Anaphylaxis in 7/39 OLE pts (mostly re-exposure) manageable via premedication. Phase 3 underway pre-filing using USS primary endpoint per FDA alignment. IP to 2040. Commercial dose 50mg daily SC. Est $500k/yr pricing vs Skyclarys $375k. TAM ~5k US pts. Risks: anaphylaxis label, Phase 3 execution, EMA approval uncertainty, Lexeo LX2006 cardiac competitor. Scenario-weighted PT $7.12 (+78% from $4).
Read full article (44 min)